Sugi Predict

Sugi Predict / Targets / CHKB

CHKB

Choline/ethanolamine kinase · Q9Y259 · CHKB on Sugi Atlas →

1,109 patent compounds predicted against CHKB, 692 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL19820633 SCHEMBL19820633 0.84 11/20
SCHEMBL19820700 SCHEMBL19820700 0.84 11/20
SCHEMBL19820724 SCHEMBL19820724 0.83 11/20
SCHEMBL19820730 SCHEMBL19820730 0.83 11/20
SCHEMBL19820651 SCHEMBL19820651 0.79 11/20
SCHEMBL19820656 SCHEMBL19820656 0.79 11/20
SCHEMBL19820762 SCHEMBL19820762 0.79 11/20
SCHEMBL19820770 SCHEMBL19820770 0.79 11/20
SCHEMBL19820705 SCHEMBL19820705 0.77 11/20
SCHEMBL21176116 SCHEMBL21176116 0.77 11/20
SCHEMBL19813942 SCHEMBL19813942 1.00 10/20
SCHEMBL19813945 SCHEMBL19813945 1.00 10/20
SCHEMBL19817172 SCHEMBL19817172 1.00 10/20
SCHEMBL19817176 SCHEMBL19817176 1.00 10/20
SCHEMBL19820477 SCHEMBL19820477 1.00 10/20
SCHEMBL19820635 SCHEMBL19820635 1.00 10/20
SCHEMBL21176065 SCHEMBL21176065 1.00 10/20
SCHEMBL21176130 SCHEMBL21176130 1.00 10/20
SCHEMBL19817241 SCHEMBL19817241 0.83 10/20
SCHEMBL19817242 SCHEMBL19817242 0.83 10/20

Clinical trials — most relevant to CHKB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis PHASE2/PHASE3NOT_YET_RECRUITING
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis PHASE2COMPLETED
Biological Effects of Quercetin in COPD PHASE1/PHASE2UNKNOWN
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression nanCOMPLETED
Human Requirements for the Nutrient Choline nanCOMPLETED
Generation of Organotypic Liver Cultures for the Identification of Biomarkers for the Prevention and Treatment of Liver Fibrosis nanUNKNOWN
Choline Dose Ranging in Postmenopausal Women nanCOMPLETED
Egg Intake, Metabolic Outcomes and Choline Levels nanRECRUITING
Choline and Brain Functioning in Postmenopausal Women nanCOMPLETED
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients. nanCOMPLETED
Maternal Choline Supplementation and Offspring Cognition in Adolescence nanENROLLING_BY_INVITATION
Choline to Improve Malnutrition and Enhance Cognition nanRECRUITING
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy. nanUNKNOWN
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Effects of Colesevelam HCl On Bile Acid Kinetics nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
The Locus Coeruleus, Norepinephrine and Cognitive Aging nanACTIVE_NOT_RECRUITING
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation nanRECRUITING
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
Supplemental Choline and Brain Development in Humans nanCOMPLETED
Impact Of Choline in Patients With NAFLD nanUNKNOWN
S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease nanUNKNOWN
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CHKB binder may also engage these)

ProteinNameSimilarity
O54783 — 0.989 O54783 →
O55229 — 0.987 O55229 →
O54804 — 0.974 O54804 →
Q9NVF9 — 0.972 Q9NVF9 →
Q01134 — 0.969 Q01134 →
D3ZRW8 — 0.968 D3ZRW8 →
Q9D4V0 — 0.965 Q9D4V0 →
A7MCT6 — 0.963 A7MCT6 →
Q8CIW5 — 0.956 Q8CIW5 →
Q96RR1 — 0.955 Q96RR1 →
Q6DC64 — 0.954 Q6DC64 →
Q91YD4 — 0.953 Q91YD4 →
Q9HBU6 — 0.951 Q9HBU6 →
CHKA Choline kinase alpha 0.951 landscape →
TRPM2 Transient receptor potential cation channel subfamily M member 2 0.950 landscape →
KDM8 Bifunctional peptidase and arginyl-hydroxylase JMJD5 0.949 landscape →
Q9N0E7 — 0.947 Q9N0E7 →
Q96FB5 — 0.946 Q96FB5 →
E9PTA2 — 0.946 E9PTA2 →
Q8IZ69 — 0.946 Q8IZ69 →
O15315 — 0.946 O15315 →
Q29RM4 — 0.945 Q29RM4 →
Q9NVE7 — 0.945 Q9NVE7 →
Q5R5F8 — 0.944 Q5R5F8 →
Q4R4U1 — 0.944 Q4R4U1 →
Q5ZIA0 — 0.944 Q5ZIA0 →
Q5R5M3 — 0.944 Q5R5M3 →
Q96AZ1 — 0.943 Q96AZ1 →
A4FV98 — 0.943 A4FV98 →
Q5RJL2 — 0.943 Q5RJL2 →